The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.本發明係關於一種醫藥組合物，其包含劑量約0.5mg至5mg，且更特定言之2mg之黃體激素受體拮抗劑，亦即(11β,17β)-17-羥基-11-[4-(甲基磺醯基)苯基]-17-(五氟乙基)雌甾-4,9-二烯-3-酮。另外，本發明係關於該新穎醫藥組合物用於治療及/或預防婦科疾病(諸如：子宮之類纖維瘤(肌瘤、子宮平滑肌瘤)、子宮內膜異位或月經出血過量)之用途，及獲得該組合物及口服劑型之方法。
